Detalhe da pesquisa
1.
The Use of Nitrosative Stress Molecules as Potential Diagnostic Biomarkers in Multiple Sclerosis.
Int J Mol Sci
; 25(2)2024 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38255863
2.
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
J Neurol Neurosurg Psychiatry
; 93(9): 978-985, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35193952
3.
Sirolimus leads to rapid and sustained clinical improvement of motor deficits in a patient with inclusion body myositis.
Eur J Neurol
; 29(4): 1284-1287, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35253967
4.
Pain, depression, and quality of life in adults with MOG-antibody-associated disease.
Eur J Neurol
; 28(5): 1645-1658, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423336
5.
Status of clinical research in neurology in Germany-A national survey.
Eur J Neurol
; 28(5): 1446-1452, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539600
6.
The STING-IFN-ß-Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis.
Int J Mol Sci
; 21(23)2020 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33291536
7.
Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
Neurology
; 103(2): e209574, 2024 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38870471
8.
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine.
Cells
; 12(9)2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37174643
9.
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Neurol Neuroimmunol Neuroinflamm
; 10(3)2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37041077
10.
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
J Neurol
; 269(5): 2806-2818, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34999925
11.
Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score-matched study.
Ther Adv Neurol Disord
; 15: 17562864221142924, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36568489
12.
A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab.
Mult Scler Relat Disord
; 59: 103670, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35150978
13.
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis.
Neurol Res Pract
; 4(1): 55, 2022 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36336685
14.
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
Front Immunol
; 13: 1037214, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36618356
15.
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
Neurol Neuroimmunol Neuroinflamm
; 8(3)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33837059
16.
Dalfampridine effects on cognition, fatigue, and dexterity.
Brain Behav
; 7(1): e00559, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28127507
17.
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells.
PLoS One
; 10(6): e0129182, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26086440
18.
Aggressive spinal cord involvement in granulomatosis with polyangiitis.
Int J Rheum Dis
; 22(4): 756-758, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30950232